Noble Financial Brokers Reduce Earnings Estimates for UNCY

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Noble Financial reduced their Q1 2027 earnings per share estimates for Unicycive Therapeutics in a research note issued on Thursday, October 22nd. Noble Financial analyst R. Leboyer now expects that the company will post earnings of ($0.14) per share for the quarter, down from their prior forecast of $0.64. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($1.16) per share. Noble Financial also issued estimates for Unicycive Therapeutics’ Q2 2027 earnings at $0.49 EPS, Q3 2027 earnings at $0.67 EPS, Q4 2027 earnings at $0.79 EPS and FY2027 earnings at $1.81 EPS.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its earnings results on Wednesday, August 12th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.41.

UNCY has been the subject of several other reports. HC Wainwright decreased their price objective on shares of Unicycive Therapeutics from $15.00 to $13.00 and set a “buy” rating for the company in a research note on Tuesday, September 29th. B. Riley Financial reiterated a “buy” rating and issued a $20.00 price objective (down from $22.00) on shares of Unicycive Therapeutics in a research note on Wednesday, August 12th. Wall Street Zen upgraded shares of Unicycive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Guggenheim reissued a “buy” rating and set a $25.00 target price (down from $37.00) on shares of Unicycive Therapeutics in a report on Thursday, August 13th. Finally, Zacks Research upgraded shares of Unicycive Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 19th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $18.25.

Unicycive Therapeutics Trading Up 0.8%

Shares of NASDAQ:UNCY opened at $3.61 on Monday. Unicycive Therapeutics has a twelve month low of $3.35 and a twelve month high of $8.74. The company’s 50 day moving average is $4.65 and its 200 day moving average is $6.12.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of UNCY. Dimensional Fund Advisors LP acquired a new stake in shares of Unicycive Therapeutics during the 1st quarter worth approximately $940,000. Seven Fleet Capital Management LP acquired a new position in shares of Unicycive Therapeutics in the 1st quarter valued at $367,000. Bank of New York Mellon Corp acquired a new position in shares of Unicycive Therapeutics in the 2nd quarter valued at $248,000. Bank of America Corp DE lifted its stake in shares of Unicycive Therapeutics by 19,327.6% in the 1st quarter. Bank of America Corp DE now owns 29,530 shares of the company’s stock valued at $194,000 after purchasing an additional 29,378 shares during the period. Finally, Renaissance Technologies LLC purchased a new stake in Unicycive Therapeutics during the first quarter worth $161,000. 40.42% of the stock is currently owned by hedge funds and other institutional investors.

Unicycive Therapeutics News Roundup

Here are the key news stories impacting Unicycive Therapeutics this week:

• Positive Sentiment: Investors who purchased Unicycive securities during the alleged class period may be eligible to seek recovery or apply to serve as lead plaintiff. The deadline is November 2, 2026. Rosen Law Firm notice
• Neutral Sentiment: Multiple firms, including Rosen, Bragar Eagel & Squire, Portnoy, Robbins, Faruqi & Faruqi, and others, issued substantially similar reminders to investors who bought UNCY shares between December 29, 2025, and June 29, 2026. These notices primarily seek potential plaintiffs and do not represent a court finding of wrongdoing. Bragar Eagel & Squire notice
• Negative Sentiment: The lawsuit alleges that Unicycive made misleading statements about its third-party manufacturer’s progress toward regaining FDA compliance, including allegedly failing to independently verify the manufacturer’s claimed remediation progress. The allegations create legal, regulatory, reputational, and potential financial risks for the clinical-stage biotechnology company. Levi & Korsinsky notice
• Negative Sentiment: The repeated litigation alerts are likely weighing on sentiment because they reinforce uncertainty surrounding manufacturing compliance and the company’s ability to advance and commercialize its kidney-disease therapies. Separately, Noble Financial reportedly reduced its earnings estimates, adding to the cautious outlook. Noble Financial earnings estimates

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc (NASDAQ: UNCY) is a clinical-stage biotechnology company focused on developing treatments for kidney disease and related metabolic complications. The company’s primary focus is hyperphosphatemia, an excess of phosphate in the blood that commonly affects people with chronic kidney disease, particularly those receiving dialysis.

Unicycive’s lead product candidate is oxylanthanum carbonate (OLC), an investigational, orally administered phosphate binder designed to bind dietary phosphate in the gastrointestinal tract and reduce its absorption into the bloodstream.